TSE:4568Pharmaceuticals
How DATROWAY’s Priority Review in Metastatic TNBC May Impact Daiichi Sankyo Company (TSE:4568) Investors
In late January and early February 2026, Daiichi Sankyo and AstraZeneca reported that the U.S. FDA accepted and granted Priority Review to their supplemental Biologics License Application for DATROWAY in unresectable or metastatic triple negative breast cancer, based on phase 3 data showing a clinically meaningful overall survival benefit versus chemotherapy.
This Priority Review, supported by robust response rates and participation in the FDA’s Project Orbis program, highlights how DATROWAY...